197 results about "Uricacidemia" patented technology

The invention discloses pediococcus acidilactici and application thereof, and relates to the technical field of microorganisms. The pediococcus acidilactici is pediococcus acidilactici Mei.1103.1, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC NO.32564, the preservation date is November 11, 2024, the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.32564. The pediococcus acidilactici Mei.1103.1 is CGMCC NO.32564. The pediococcus acidilactici Mei.1103.1. The invention also provides application of the fermented dry rice flour in preparation of products for reducing uric acid, preventing / treating hyperuricemia, regulating immunity, preventing / treating kidney injury and preventing / treating fatty liver and fermented dry rice flour. The bacterium can reduce uric acid and relieve hyperuricemia; regulating blood fat; kidney and liver injuries caused by hyperuricemia are repaired; the content of volatile flavor compounds in the fermented dry rice flour is increased.

The invention discloses application of lactobacillus rhamnosus HPT112 in preparation of a medicine for preventing and / or treating hyperuricemia, and belongs to the field of microorganisms, the lactobacillus rhamnosus HPT112 is preserved in the China Center for Type Culture Collection on November 20, 2023, and the preservation number is CCTCC NO: M20232273. Tests prove that the lactobacillus rhamnosus HPT112 has the function of regulating bile acid metabolism, so that the uric acid reducing effect is achieved, and the uric acid reducing effect equivalent to or even better than that of an existing hyperuricemia medicine can be achieved. Compared with existing hyperuricemia drugs, the lactobacillus rhamnosus HPT112 has the advantages that toxic and side effects are low, safety is high, a brand-new drug for preventing and / or treating hyperuricemia can be developed by the aid of the lactobacillus rhamnosus HPT112, and accordingly inflammatory reaction caused by hyperuricemia can be prevented and / or treated.

The invention discloses an intestinal strain capable of effectively regulating uric acid metabolism, a microbial agent of the intestinal strain and application of the intestinal strain in uric acid reducing products, and belongs to the technical field of microorganisms. According to the enterococcus pluvialis ZQ205, the enterococcus pluvialis ZQ205 which is free of toxic and side effects and capable of effectively relieving and treating the hyperuricemia is found for the first time, and the collection number of the enterococcus pluvialis ZQ205 in the China Center for Type Culture Collection is CCTCC NO: M 2025844; the strain can significantly reduce the levels of uric acid, creatinine and urea nitrogen in serum of mice, can effectively reduce the levels of inflammatory factors such as IL-6 and TNF-alpha in serum of hyperuricemia mice, and can improve kidney injury caused by hyperuricemia.

The invention discloses a plant lactobacillus and an application thereof in fermentation of sophora flowers for relieving hyperuricemia. The name of the lactobacillus plantarum is lactobacillus plantarum WH-JS4, the lactobacillus plantarum WH-JS4 is preserved in Guangdong Microbial Culture Collection Center on November 7, 2024, and the preservation number of the lactobacillus plantarum WH-JS4 is GDMCC No: 65437, the GDMCC No: 65437. The lactobacillus plantarum WH-JS4 is named as lactobacillus plantarum WH-JS4. The lactobacillus plantarum WH-JS4 is named as lactobacillus plantarum WH-JS4. The lactobacillus plantarum WH-JS4 is named as lactobacillus plantarum WH-JS4. The plant lactobacillus WH-JS4 can be used for sophora flower fermentation, sophora flower fermentation liquor obtained through fermentation has a good uric acid reducing effect, and the plant lactobacillus WH-JS4 can be used for developing functional products for preventing or treating hyperuricemia.

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.

The invention relates to an application of a sugarcane polyphenol extract in preparation of a medicine for preventing and / or treating hyperuricemia. The invention also discloses application of the sugarcane polyphenol extract in medicines or health care products for gout caused by hyperuricemia, chronic gout, liver injury and kidney injury. The technical problem to be solved is how to provide the sugarcane polyphenol extract, the sugarcane polyphenol extract contains at least 32 polyphenol monomers, the uric acid reducing effect is improved through the synergistic effect among the polyphenol monomers, and the sugarcane polyphenol extract can be used for preparing drugs or health care products for preventing and / or treating hyperuricemia.

The invention discloses a preparation method and application of a medicinal and edible traditional Chinese medicine compound with an effect of treating uric acid diseases. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 to 25 parts of semen plantaginis, 15 to 25 parts of pawpaw, 5 to 15 parts of rhizoma smilacis glabrae, 5 to 15 parts of herba portulacae, 1 to 11 parts of radix glycyrrhizae preparata, 5 to 15 parts of folium mori, 5 to 15 parts of folium perillae, 1 to 11 parts of semen pruni, 5 to 15 parts of rhizoma polygonati, 1 to 11 parts of black dates and 1 to 9 parts of mulberries. The traditional Chinese medicine compound is composed of medicinal and edible raw materials, has stable efficacy of reducing uric acid and relieving uric acid liver and kidney injury, renal fibrosis and gouty arthritis, can relieve arthrocele caused by gout, reduces the level of joint inflammatory factors and the like, and takes effect quickly. The traditional Chinese medicine composition can be used for treating hyperuricemia, uric acid nephropathy, gouty arthritis and hyperuricemia accompanying symptoms.

Disclosed in the present invention is an siRNA for inhibiting the expression of a urate transporter 1 (URAT1) gene in human cells. In the present invention, a plurality of siRNAs capable of inhibiting URAT1 expression are obtained by screening, and on this basis, appropriate modifications are performed to obtain sequences with improved target silencing ability. Drugs with the siRNAs as active ingredients are expected to be clinically applicable in the prevention and treatment of diseases related to the URAT1 target, such as gout, hyperuricemia, gouty arthritis and renal calculi.

The invention discloses a marine fish uric acid lowering peptide with kidney protection activity as well as a preparation method and application of the marine fish uric acid lowering peptide. The marine fish uric acid reducing peptide Trp-Gly-Val-Pro-Glu, WGVPE for short, with kidney protection activity is prepared, and the marine fish uric acid reducing peptide Trp-Gly-Val-Pro-Glu, WGVPE for short, can remarkably reduce the blood uric acid level in a body, promote uric acid excretion and improve pathological damage of the kidney. In addition, the pentapeptide provided by the invention can be used in common food, food additives and functional food for preventing and treating hyperuricemia and kidney injury or health care products or medicines for relieving hyperuricemia and kidney injury, and has a good application prospect.

The present invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition and its use for preventing or treating hyperuricemia. The technical problem to be solved by the present invention is to provide a new option for treating hyperuricemia. The technical solution of the present invention is a traditional Chinese medicine composition for preventing or treating hyperuricemia, comprising the following ingredients: thistle, gardenia, bamboo leaves, angelica, lily, corn silk, broccoli seed extract, and eucommia leaves. The traditional Chinese medicine composition of the present invention has the effects of inhibiting uric acid synthesis, promoting uric acid excretion, improving kidney damage, and protecting the liver.

The invention relates to a food-borne melanin-containing uric acid-reducing food composition which is prepared by mixing 2-10 parts by weight of celery seed extract, 1-6 parts by weight of food-borne melanin and 0-5 parts by weight of astragalus extract, plays a role in reducing uric acid by inhibiting the activity of xanthine oxidase, and has a better effect of treating hyperuricemia and / or gout. The liver and kidney injury caused by hyperuricemia can be improved, the toxic and side effects are low, and the food can be eaten for a long time.

The invention belongs to the technical field of biological medicine, and relates to application of a clerodendranthus spicatus tea bag in regulating intestinal excretion and reducing uric acid. One of the purposes of the invention is to provide the application of the clerodendranthus spicatus teabag in regulating intestinal tracts to reduce uric acid According to a preferred embodiment, the clerodendranthus spicatus teabag regulates ATP binding cassette transporter G2 and inhibits uricase activity. The invention provides the application of the clerodendranthus spicatus teabag in regulating the intestinal microbial environment and reducing uric acid, and the clerodendranthus spicatus teabag has remarkable beneficial effects. The clerodendranthus spicatus teabag can effectively regulate the structure and the function of intestinal microflora, especially the enrichment amount of characteristic bacteria Muriaculum in the intestinal tract, further strengthens the probiotic activity of the intestinal flora, and is helpful for maintaining the steady state of uric acid in the body. The multi-way synergistic effect not only provides an innovative strategy for preventing and treating hyperuricemia and related metabolic diseases, but also avoids side effects possibly brought by traditional medicines, and shows good application prospects and clinical values.

The invention belongs to the field of biological medicine, and particularly relates to application of urolithin D in preparation of medicine for relieving hyperuricemia. It is found for the first time that the urolithin D can significantly reduce the level of serum uric acid, improve the expression disorder of a kidney urate transporter, efficiently relieve or treat hyperuricemia and related diseases thereof, and relieve kidney injury and fibrosis; and the compound can be used for preparing medicines for treating hyperuricemia and related diseases, is low in cost and good in safety, and has a wide application prospect.

A food medicine for reducing blood uric acid and treating gout is characterized in that celery seeds, celery, mulberry fruits, mulberry leaves, sea buckthorn fruit powder, dandelions, rhizoma polygonati, poria cocos and beach kidney grass serve as a basic formula; the auxiliary materials comprise one, several or all of a plurality of formula combinations of ramulus mori, lycium ruthenicum, radix puerariae, Chinese yam, clerodendranthus spicatus, lysimachia christinae hance, acanthopanax, anserine, astragalus membranaceus, purslane, herba cepbalanoplosis segeti, galangal, hovenia dulcis thunb, astragalus membranaceus, luteolin, uric acid-reducing edible probiotics and the like, and are used for treating hyperuricemia and gout.

The invention belongs to the technical field of biological medicines, and particularly relates to a cordyceps sobolifera fermentation extract for reducing uric acid as well as a preparation method and application of the cordyceps sobolifera fermentation extract. The method comprises the following steps: concentrating cordyceps sobolifera fungus fermentation liquor, then leaching with ethanol, concentrating leaching liquor, then sequentially extracting with n-butyl alcohol, ethyl acetate and petroleum ether, and concentrating extracts to respectively obtain an n-butyl alcohol extraction part, an ethyl acetate extraction part, a petroleum ether extraction part and a residual part, the obtained petroleum ether extract is the cordyceps sobolifera fermentation extract for reducing uric acid. The cordyceps sobolifera fermentation extract disclosed by the invention has the effects of remarkably relieving kidney injury of a mouse with hyperuricemia and reducing serum uric acid of the mouse with hyperuricemia. As a novel natural uric acid-reducing active substance, the cordyceps sobolifera fermentation extract disclosed by the invention can be applied to the fields of health foods and medicines, and has good development and application values.

The invention relates to the technical field of medicine, in particular to application of 5-bromocytidine in medicine for treating hyperuricemia, the 5-bromocytidine can effectively reduce the content of uric acid in serum, namely, the 5-bromocytidine has the effect of treating the hyperuricemia.

The invention relates to lactobacillus reuteri SAU-R-8 which is derived from Tibet naturally-fermented sour yak milk and is used for producing exopolysaccharides and application of the lactobacillus reuteri SAU-R-8 in reducing uric acid, and belongs to the technical field of microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30373, and the preservation date is April 19, 2024. The lactobacillus reuteri SAU-R-8 provided by the invention is screened from yak yogurt naturally fermented from herdsmen in the Sankarst region of Tibet, the yield of exopolysaccharides in an MRS culture medium reaches 318.57 mg / L, nucleoside substances such as inosine and guanosine can be efficiently degraded, purine substances such as guanine can be efficiently absorbed, the activity of xanthine oxidase can be inhibited, and the lactobacillus reuteri SAU-R-8 can be used for preparing the yak yogurt. The method can be further applied to product development for relieving or treating hyperuricemia.

The invention discloses a novel application of Wickerhamomyces anomalus YFJ252 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28267) which is disclosed and preserved, in particular relates to an application of the strain and a metabolite of the strain in preparation of medicines, foods or health care products for preventing or treating hyperuricemia (HUA), and belongs to the technical field of microorganisms. The strain has excellent probiotic characteristics (acid and cholate resistance, high hydrophobicity, self-aggregation and co-aggregation capability, oxidation resistance, glycometabolism regulation, anti-inflammatory capability and the like) and a function of inhibiting the activity of xanthine oxidase (XO) in vitro. The serum uric acid, creatinine and urea nitrogen levels of a hyperuricemia mouse model induced by high fructose diet and oteracil potassium can be remarkably controlled, and a new way is provided for safely and effectively preventing HUA.

The invention relates to the technical field of traditional Chinese medicines, and discloses application of an active ingredient of shiny-leaved yellowhorn leaves in preparation of a medicine for treating hyperuricemia. The xanthoceras sorbifolia leaf active ingredients comprise quercitrin, rutin and myricetin; the content of quercitrin is 0.2508 mg / g to 0.6719 mg / g, the content of rutin is 0.6707 mg / g to 1.5831 mg / g, and the content of myricetin is 0.8002 mg / g to 3.4858 mg / g. According to the invention, myricetin, quercitrin and rutin are determined as core effective substances of shiny-leaved yellowhorn leaves for treating hyperuricemia for the first time; the multi-target and multi-channel action mechanism is disclosed; meanwhile, network pharmacological analysis shows that the three components have high connectivity in a network and jointly act on key targets such as XOD, ACE, AKR1B1 and TNF, it is prompted that the three components do not act singly, but play a treatment role through multi-target and multi-channel cooperation, the traditional'single target-single drug 'thinking is changed into a'multi-component-multi-target-multi-channel' system regulation mode, and the treatment effect is improved. A new thought is provided for comprehensive treatment of the hyperuricemia.

The embodiments of the present invention relate to the field of information processing, and disclose a recognition device based on ultrasonic images. It includes: an acquisition module, which is used to acquire ultrasonic images of different parts of the user; a recognition module, which is used to use a preset set of N training models to identify each characteristic symptom existing in the ultrasonic image; a scoring module, which is used to obtain the user's scoring result based on the characteristic symptoms existing in the ultrasonic image, and the preset correspondence between each characteristic symptom and the score value; an output module, which is used to output the user's test result based on the scoring result and the preset score threshold. In an embodiment of the present invention, by collecting ultrasonic images of various parts, using a training model to analyze the ultrasonic images, and then scoring the user according to the analyzed characteristic symptoms, the user's health status is converted into a visual numerical value, providing a quantitative indicator for the severity of gout or asymptomatic hyperuricemia.

The invention discloses phthalide compounds as well as a preparation method and application thereof. The phthalide compounds comprise a compound 1 and a compound 2 as well as a preparation method and application thereof. The two compounds are separated and purified from the ethyl acetate extract of the traditional Chinese medicine ligusticum wallichii for the first time. An in-vitro biological activity test shows that the two compounds have obvious inhibitory activity on xanthine oxidase, which indicates that the two compounds can be used as novel potential candidate drugs for treating hyperuricemia and gout. The embodiment of the invention provides a preparation method, structural identification and pharmacological action of the two phthalide compounds, and provides a new strategy for treatment of hyperuricemia and gout diseases.

The present invention provides a pharmaceutical composition comprising a therapeutically effective amount of allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating cardiovascular disease, in which the composition is administered to a subject having a serum uric acid level of 6 mg / dl or higher to reduce the serum uric acid level of the subject to less than 6 mg / dl. Therefore, the pharmaceutical composition according to the present invention exhibits an excellent effect on xanthine oxidase inhibitor and is administered to selected subjects to effectively treat or prevent cardiovascular disease.

The invention belongs to the field of medical chemistry, and relates to a benzopyrone compound, a benzopyrone composition and application of the benzopyrone compound and the benzopyrone composition in preparation of a medicine for treating hyperuricemia. The chemical structure is as shown in formula I; in the formula, R1 is fluorine or hydrogen; r2 is fluorine or hydrogen; r3 is hydrogen, nitryl or tertiary butyl; r4 is hydrogen, fluorine or trifluoromethyl; and R1, R2, R3 and R4 are not hydrogen at the same time. The benzopyrone compound provided by the invention has good inhibitory activity on XOD, and can reduce the level of uric acid, thereby being beneficial to treatment of hyperuricemia.

The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for treating hyperuricemia, renal damage and fibrosis, and its application. The technical problem to be solved by the present invention is to provide a new option for the treatment of hyperuricemia. The technical solution of the present invention is a traditional Chinese medicine composition for treating hyperuricemia, renal damage and fibrosis, comprising the following ingredients: mistletoe, phellodendron, oriental water chestnut, ginseng, astragalus, polygonatum, lotus leaf, cirsium japonicum and panax notoginseng. The traditional Chinese medicine composition of the present invention has the effects of inhibiting uric acid synthesis, promoting uric acid excretion, and improving renal damage, and can be used to treat hyperuricemia without causing liver damage.

The invention relates to application of puerarin peptide in preparation of anti-inflammatory and / or uric acid-reducing drugs, and relates to the technical field of drugs. The preparation method of the kudzuvine root peptide comprises the following steps: taking kudzuvine root, extracting to obtain soluble protein, dialyzing to obtain dialyzed protein, performing enzymolysis to obtain crude polypeptide, and purifying to obtain the kudzuvine root peptide. The puerarin peptide is high in purity and strong in activity, can remarkably inhibit inflammatory reaction, reduce the level of inflammatory factors and effectively relieve inflammatory symptoms, and provides a new efficient natural medicine choice for treatment of inflammatory diseases; meanwhile, the pharmaceutical composition can effectively reduce the serum uric acid level of a hyperuricemia animal model, regulate uric acid transport related gene expression to promote uric acid excretion and improve renal functions and histopathologic injury, shows a good uric acid reducing effect, is high in safety and free of obvious toxic and side effects, and is expected to become an innovative medicine for treating hyperuricemia and gout.

This invention discloses an early screening system and method for hyperuricemia based on fingertip blood uric acid detection. The system includes a fingertip blood collection module, a detection module, a data processing module, a storage module, an analysis module, an early warning module, a display module, a communication module, a calibration module, and a power supply module. It accurately collects fingertip blood samples from subjects, obtains blood uric acid concentration data using specific detection equipment, constructs a multi-dimensional analysis model based on clinical characteristic parameters, and determines the optimal diagnostic cutoff value based on ROC curves, achieving rapid and accurate screening for hyperuricemia. The method includes steps such as sample collection, detection, data processing, model analysis, result determination, and early warning. It is simple to operate, fast, and highly accurate, solving the problems of poor compliance and difficulty in grassroots implementation associated with traditional venous blood testing. It is suitable for large-scale population screening and early diagnosis of hyperuricemia in areas with scarce medical resources, and has significant clinical application value and social significance.

The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for treating hyperuricemia. The medicine composition is prepared from the following components in parts by weight: 50 to 100 parts of radix bupleuri, 50 to 100 parts of cortex moutan, 10 to 50 parts of radix codonopsis, 10 to 50 parts of radix clematidis, 10 to 50 parts of rhizoma dioscoreae colletii, 10 to 50 parts of rhizoma smilacis glabrae, 1 to 30 parts of fructus lycii and 1 to 30 parts of liquorice root. The pharmaceutical composition embodies the synergistic effect of traditional Chinese medicines, not only can reduce the content of uric acid and creatinine, but also can reduce the activity of xanthine oxidase, and has an exact effect of treating hyperuricemia. After the pharmaceutical composition is taken for a long time, ALT and AST in biochemical indexes of liver functions do not change obviously, so that the pharmaceutical composition does not cause damage to the liver functions, is safe to the liver and does not have toxic or side effects.

The invention discloses an external traditional Chinese medicine formula for reducing uric acid and a preparation method thereof. The invention relates to a pharmaceutical composition for reducing uric acid, in particular to a medicament for reducing uric acid, which is prepared from plant Chinese herbal medicines as raw materials. Hyperuricemia is a common disease in modern society, brings great pain to patients, and urgently needs a traditional Chinese medicine preparation which can efficiently relieve hyperuricemia and keep blood uric acid constant. Therefore, development of a traditional Chinese medicine preparation which is efficient, convenient to use and small in side effect has important significance. The invention firstly discloses the external traditional Chinese medicine composition for reducing uric acid. The external traditional Chinese medicine composition comprises rhizoma atractylodis, cortex phellodendri, radix cyathulae, semen coicis, garden balsam stem, spina gleditsiae, sargentgloryvine stem, lycopodium clavatum, radix paeoniae alba and rhizoma smilacis glabrae. The traditional Chinese medicine composition has the advantages that the traditional Chinese medicine composition is high in acid discharge effect, and uric acid can be obviously reduced; the preparation method of the external preparation provided by the invention is simple and easy to implement.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition, its preparation method, and its uses. By mass parts, the raw materials of the traditional Chinese medicine composition include: 20-60 parts of Acorus calamus, 30-50 parts of Citrus aurantium, 20-60 parts of Benzoin, and 40-100 parts of Catechu. The traditional Chinese medicine composition of this invention has simple and natural components, and clear efficacy. It can effectively reduce the levels of XOD, SUA, CRE, BUN, TNF-α, IL-6, D-Lac, and DAO in the serum of a mouse model of gout, and significantly reduce the renal index, demonstrating good efficacy in treating hyperuricemia and / or gout.

The invention discloses a composition and application thereof in preparation of a product for reducing uric acid and / or preventing and treating hyperuricemia. The composition is prepared from the following components in parts by weight: 0.04 to 0.18 part of SOD (superoxide dismutase), 1 to 10 parts of trehalose, 17 to 34 parts of green wheat seedling powder and 55 to 81 parts of milk. The composition can safely and effectively reduce uric acid in serum of an animal body, plays a role in treating hyperuricemia, and has the advantage of good palatability.